Hyperion DeFi(HYPD)
$2.08-0.26 (-11.11%)
HYPD
Hyperion DeFi stock drug pipeline
$2.08
At close:-0.26 (-11.11%)
Want to see HYPD full AI Analyst Report?
Hyperion DeFi (HYPD) Drug Pipeline
969 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution | Mydriasis | Phase IV | Completed | Evaluation of Pupil Dilation Speed With the MAP Dispenser | May 25, 2021 | ― |
| Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution | Myopia | Phase III | Terminated | Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression | May 07, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution | Phase IV | Mydriasis | Completed | Evaluation of Pupil Dilation Speed With the MAP Dispenser | May 25, 2021 | ― |
| Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution | Phase III | Myopia | Terminated | Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression | May 07, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Hyperion Defi, Inc. (HYPD) have in its pipeline
Hyperion DeFi HYPD is currently developing the following drugs: Tropicamide-Phenylephrine Fixed Combination Ophthalmic Solution, Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

